甘精胰島素+阿卡波糖治療老年糖尿病患者的臨床效果及預(yù)后分析
發(fā)布時(shí)間:2018-06-24 來(lái)源: 散文精選 點(diǎn)擊:
[摘要] 目的 研究甘精胰島素+阿卡波糖治療老年糖尿病患者的臨床療效及預(yù)后效果。方法 選取2014年6月—2017年6月該院收治的48例老年糖尿病患者作為研究對(duì)象,按照數(shù)字隨機(jī)法將患者分成兩組,一組采用甘精胰島素進(jìn)行治療,為常規(guī)組,另一組則采用甘精胰島素+阿卡波糖進(jìn)行治療,為研究組,對(duì)比分析兩組患者的治療效果和預(yù)后效果。結(jié)果 研究組患者治療后與隨訪臨床指標(biāo)對(duì)比差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05),各項(xiàng)數(shù)據(jù)與常規(guī)組對(duì)比差異有統(tǒng)計(jì)學(xué)意義(P<0.05);常規(guī)組患者治療后與隨訪數(shù)據(jù)中2 hPG、HbAlc、FCP 3項(xiàng)數(shù)據(jù)對(duì)比差異有統(tǒng)計(jì)學(xué)意義(P<0.05);常規(guī)組不良反應(yīng)發(fā)生了為25%(6例),高于研究組的4.17%(1例)(P<0.05)。結(jié)果 甘精胰島素+阿卡波糖治療老年糖尿病患者療效明顯,可有效改善患者各項(xiàng)臨床指標(biāo),且維持時(shí)間長(zhǎng),預(yù)后效果佳,安全性也遠(yuǎn)優(yōu)于單獨(dú)使用甘精胰島素,該用藥方式在老年糖尿病患者的治療中具有較高的使用價(jià)值。
[關(guān)鍵詞] 甘精胰島素;阿卡波糖;糖尿;老年患者
[中圖分類號(hào)] R587.1 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1672-4062(2017)11(b)-0056-02
[Abstract] Objective To research the clinical effect and prognosis of insulin glargine combined with acarbose in treatment of senile diabetes patients. Methods 48 cases of senile diabetes patients admitted and treated in our hospital from June 2014 to June 2017 were selected as the research objects and randomly divided into two groups, the routine group were treated with insulin glargine, while the research group were treated with insulin glargine combined with acarbose, and the treatment effect and prognosis effect were compared between the two groups. Results The differences in the clinical follow-up indicators after treatment between the two groups were not statistically significant(P>0.05), and the differences in various data between the two groups were statistically significant(P<0.05), and the differences in the 2 hPG, HbAlc, FCP between the two groups after treatment were statistically significant(P<0.05), and the incidence rate of adverse reactions in the routine group was higher than that in the research group(25% vs 4.17%, 6 cases vs 1 case)(P<0.05). Conclusion The curative effect of insulin glargine combined with acarbose in treatment of senile diabetes patients is obvious, which can effectively improve various clinical indicators, with long maintenance time, and good prognosis effect, and the safety is much better than that of single insulin glargin, which is of higher application value in treatment.
[Key words] Insulin glargine; Acarbose; Diabetes; Senile patients
糖尿病是一種臨床常見(jiàn)的內(nèi)分泌系統(tǒng)疾病,病理特征表現(xiàn)為胰島素功能異常、血糖水平異常上升,長(zhǎng)期的胰島素分泌異常可導(dǎo)致患者消瘦、疲乏無(wú)力,糖尿病同時(shí)伴有多種并發(fā)癥[1]。糖尿病的治療是一個(gè)漫長(zhǎng)的過(guò)程,需要終身服藥,常見(jiàn)藥物有雙胍類降糖藥、胰島素等等。在長(zhǎng)期的臨床實(shí)踐中發(fā)現(xiàn),聯(lián)合用藥比單一的使用某一種藥物的效果更佳。為了明確甘精胰島素+阿卡波糖治療老年糖尿病患者的臨床療效及預(yù)后效果,該院對(duì)2014年6月—2017年6月收治的48例老年糖尿病患者進(jìn)行了分組研究,現(xiàn)報(bào)道如下。
1 資料與方法
1.1 一般資料
選取該院收治的48例老年糖尿病患者作為研究對(duì)象,按照數(shù)字隨機(jī)法將患者分成兩組,一組為常規(guī)組,另一組為研究組,每組24例患者。常規(guī)組中有男性患者13例,女性患者11例,患者年齡66~87歲,平均年齡(73.2±1.6)歲,患者病程5~21年,平均病程(12.4±0.6)年;研究組中有男性患者11例,女性患者13例,患者年齡65~86歲,平均年齡(72.4±1.5)歲,患者病程5.5~22年,平均病程(13.4±0.6)年。所有患者及其家屬均同意該次分組治療方案,兩組患者一般資料對(duì)比差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05),具有可比性。
相關(guān)熱詞搜索:預(yù)后 胰島素 糖尿病患者 阿卡 臨床
熱點(diǎn)文章閱讀